Gout Therapeutics

Global Gout Therapeutics Market to Reach US$10.8 Billion by 2030

The global market for Gout Therapeutics estimated at US$5.1 Billion in the year 2024, is expected to reach US$10.8 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2024-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Urate-Lowering Agents segment is estimated at 15.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 17.5% CAGR

The Gout Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 17.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 11.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR.

Global Gout Therapeutics Market - Key Trends and Drivers Summarized

How Is the Gout Therapeutics Market Evolving with the Rise in Chronic Diseases?

Gout is a chronic form of arthritis caused by elevated levels of uric acid in the blood, leading to the formation of painful crystals in joints. Gout therapeutics are essential in managing this condition, which is becoming increasingly common due to lifestyle factors such as poor diet, obesity, and the aging population. The rising prevalence of gout is prompting a growing demand for effective therapies that can manage both acute flare-ups and long-term uric acid levels. Traditional treatments like nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine are still widely used, but there is a significant shift towards novel urate-lowering therapies, such as xanthine oxidase inhibitors and biologics, aimed at providing better control of the condition and minimizing side effects.

What Are the Key Segments and Types of Gout Therapeutics?

Drug classes include NSAIDs, corticosteroids, colchicine, and urate-lowering therapies such as allopurinol, febuxostat, and pegloticase. Urate-lowering drugs are gaining more attention due to their efficacy in preventing recurrences and managing chronic gout. The market can also be divided into acute and chronic treatment types, where acute treatments are aimed at relieving pain and inflammation during a flare-up, while chronic treatments focus on lowering uric acid levels to prevent future attacks. Oral medications dominate the market, but injectable biologics are increasingly being used in severe cases of refractory gout. Geographically, North America and Europe lead the market due to high disease prevalence and advanced healthcare infrastructure, while the Asia-Pacific region is growing rapidly due to increasing awareness and healthcare access.

How Are Technological Advances Shaping the Future of Gout Treatment?

Technological advancements in gout therapeutics are transforming the way the disease is managed, particularly with the rise of biologics and personalized medicine. Biologics like pegloticase, which is used to treat severe, refractory gout, have proven effective where traditional treatments have failed. Additionally, research into genetic markers and personalized treatment plans is gaining traction, allowing for tailored therapies based on an individual’s specific uric acid metabolism. Continuous innovation in drug delivery systems, such as extended-release formulations and injectable biologics, is enhancing patient compliance and providing more sustained control of uric acid levels. Moreover, telemedicine and digital health platforms are facilitating better patient-doctor communication, enabling real-time monitoring and adjustments to treatment plans, particularly for long-term management.

What Factors Are Driving the Growth in the Gout Therapeutics Market?

The growth in the gout therapeutics market is driven by several factors, including the increasing prevalence of gout worldwide, especially in developed nations where lifestyle-related risk factors such as poor diet and obesity are on the rise. The growing aging population, who are more susceptible to chronic conditions, is also boosting the demand for effective gout management. Furthermore, advancements in drug development, particularly the rise of biologics and novel urate-lowering therapies, are expanding treatment options for patients with refractory gout. Increased awareness of gout as a serious chronic condition, rather than just an acute issue, is driving earlier diagnosis and treatment, while improved healthcare infrastructure in emerging markets is broadening access to advanced therapies.

SCOPE OF STUDY:

The report analyzes the Gout Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (NSAIDs, Urate-Lowering Agents, Colchicine, Corticosteroids); Disease Condition (Chronic Gout, Acute Gout)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• AstraZeneca plc
• GlaxoSmithKline plc
• Grunenthal Group
• Horizon Pharma Plc
• Ironwood Pharmaceuticals, Inc.
• JW Pharmaceutical
• Merck& Co., Inc.
• Novartis AG
• Regeneron Pharmaceuticals.
• Savient Pharmaceuticals
• Selecta Biosciences, Inc.
• Takeda Pharmaceutical Company Ltd.
• Teijin Pharma Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.